Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with ...

BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...

Tempest Therapeutics, Inc. (NASDAQ:TPST), a pharmaceutical company with a market capitalization of $27.87 million, announced Monday that it has successfully regained compliance with the Nasdaq’s ...

Tempest Therapeutics Inc. advanced stock charts by Barron's. View TPST historical stock data and compare to other stocks, and exchanges.

BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...

Tempest Therapeutics presents new data on amezalpat's immune response at the 2025 AACR Annual Meeting, highlighting its cancer treatment potential. Tempest Therapeutics, Inc. announced new data at ...

Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a ...